[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"American Hip Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,64,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100562880","phase-4-peri-operative-testosterone-administration-in-primary-total-hip-arthroplasty-100562880",false,"NCT06608914","Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty","Inclusion Criteria:\n\n* Male patients over the age of 18 with a diagnosis of osteoarthritis or dysplasia that are undergoing total hip replacement will be recruited to the study and screened for eligibility. Inclusion criteria include clinical diagnosis of osteoarthritis or dysplasia, age 18 and older, and hypogonadism, defined as a testosterone level \\<300ng\u002FdL or clinical signs of hypogonadism including reduced muscle mass and strength, decreased libido, erectile dysfunction, loss of body hair, low bone mineral density, infertility, gynecomastia, or incomplete or delayed sexual development.\n\nExclusion Criteria:\n\n* Major exclusion criteria include previous arthroplasty of the affected hip, previous spine surgery, a past medical history significant for allergy to testosterone, prostate cancer, PSA \\>4 ng\u002Fml, breast cancer, polycythemia, diabetes mellitus with a HbA1c \\> 7, BMI \\<18 or \\> 40, and preoperative motion or strength limitations that will affect postoperative rehabilitation.",true,"MALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","It is often observed that patients following total hip replacement have a hard time with rehabilitation, as patients commonly lose muscle mass and strength around the surgical site. The goal of this study is to learn if giving patients testosterone around their hip surgery can prevent them from losing muscle mass, as well as to see if it will improve their outcomes after surgery. The main question this study aims to answer is: Will perioperative testosterone administration increase lean mass in addition to improving functional and clinical patient reported outcomes greater than placebo?\n\nResearchers will compare patients who were administered testosterone to standard of care (no administration of testosterone) to see if there is a difference in their recovery and outcomes.\n\nParticipants will be given either testosterone or saline for eight weeks beginning two weeks prior to surgery. Participants will have to answer questionnaires on how they are doing, as well as will do other testing during this time.",[26],"Osteoarthritis, Hip",[28,29,30,31],"testosterone","hypogonadism","total hip replacement","total hip arthroplasty","NOT_YET_RECRUITING","2024-12-30",{"date":35,"type":36},"2025-01-01","ACTUAL",{"date":38,"type":20},"2025-01",{"date":40,"type":20},"2026-12",{"name":42,"class":43},"American Hip Institute","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":63,"locationsCount":4},"100551622","phase-4-peri-operative-testosterone-administration-in-primary-hip-arthroscopy-100551622","NCT06462482","Peri-Operative Testosterone Administration in Primary Hip Arthroscopy","Inclusion Criteria:\n\n* Male patients over the age of 18 with a diagnosis of femoroacetabular impingement (FAI) with labral tear will be recruited to the study and screened for eligibility. Inclusion criteria include clinical diagnosis of FAI, age 18 and older, and hypogonadism, defined as a testosterone level \\\u003C300ng\u002FdL.\n\nExclusion Criteria:\n\n* . Major exclusion criteria include previous surgery to the affected hip or spine, LCEA \\\u003C 18, a past medical history significant for allergy to testosterone, prostate cancer, PSA \\> 4 ng\u002Fml, breast cancer, polycythemia, diabetes mellitus with a HbA1c \\> 7, BMI \\\u003C 18 or \\> 40, and preoperative motion or strength limitations that will affect postoperative rehabilitation.","90 Years",{"count":19,"type":20},[23],"It is often observed that patients following hip surgery have a hard time with rehabilitation, as patients commonly lose muscle mass and strength around the surgical site. The goal of this study is to learn if giving patients testosterone around their hip surgery can prevent them from losing muscle mass, as well as to see if it will improve their outcomes after surgery. The main question this study aims to answer is: Will perioperative testosterone administration increase lean mass in addition to improving functional and clinical patient reported outcomes greater than placebo?\n\nResearchers will compare patients who were administered testosterone to standard of care (no administration of testosterone) to see if there is a difference in their recovery and outcomes.\n\nParticipants will be given either testosterone or saline for eight weeks beginning two weeks prior to surgery. Participants will have to answer questionnaires on how they are doing, as well as will do other testing during this time.",[55],"Femoro Acetabular Impingement",[57,58,59],"Testosterone","Hypogonadism","Hip arthroscopy",{"date":35,"type":36},{"date":38,"type":20},{"date":40,"type":20},{"name":42,"class":43},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100554536","phase-4-knotless-implants-as-an-alternative-for-capsular-closure-in-primary-hip-arthroscopy-a-prospective-multi-center-study-100554536","NCT06500364","Knotless Implants As an Alternative for Capsular Closure in Primary Hip Arthroscopy: a Prospective, Multi-Center Study","Inclusion Criteria:\n\n* Patients undergoing a primary hip arthroscopy\n* Patients younger than 60 years old.\n* Patients who will receive capsular closure with the Arthrex LoopLocTM device following hip arthroscopy.\n\nExclusion Criteria:\n\n* Patients that had previous hip surgery,\n* Patients that had a center edge angle (CEA) less than 25 degrees or greater than 40 degrees.\n* Patients that have a cartilage damage grade greater than or equal to 3.","ALL","60 Years",{"count":73,"type":20},80,[23],"The purpose of this research is to see if the Arthrex LoopLocTM device is better for capsular closure during hip arthroscopy than other treatments available.\n\nThe hip capsule is the tissue that surrounds your hip joint. It stabilizes and supports your hip joint. During hip arthroscopy, this tissue must be cut through in order to perform the hip arthroscopy. Once the hip arthroscopy is completed, the surgeon might repair the capsule. Current ways of repairing the capsule include knotted suture that might irritate structures around the hip, leading to the possible formation of scar tissue and pain. The Arthrex LoopLocTM device is knotless and may lower the presence of irritation and scar tissue around the hip after surgery and might lead to better outcomes.\n\nTherefore, researchers will compare patients who had the LoopLocTM device used to close their hip capsule during surgery to those who did not have the device used, to see if there is a difference in their outcomes following surgery.",[55],[59,78],"Hip capsule","RECRUITING",{"date":35,"type":36},{"date":82,"type":36},"2024-10-29",{"date":84,"type":20},"2027-08",{"name":42,"class":43},1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":70,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100573782","phase-4-intraoperative-bone-marrow-aspirate-concentrate-injections-evaluating-outcomes-in-a-randomized-controlled-trial-100573782","NCT06750757","Intraoperative Bone Marrow Aspirate Concentrate Injections: Evaluating Outcomes in a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients undergoing primary hip arthroscopy to treat femoroacetabular impingement\n* Subjects will require a clinical diagnosis of intra-articular pathology consisting of anterior hip and\u002For groin pain with restricted hip motion and positive impingement testing.\n* Study inclusion also requires the radiographic hallmarks of Cam type femoroacetabular impingement with an alpha angle greater than 60 degrees on Dunn lateral views and advanced imaging with magnetic resonance imaging (MRI) or magnetic resonance arthrography (MRA) confirming chondrolabral pathology.\n\nExclusion Criteria:\n\n* Patients who have had prior hip arthroscopy or hip surgery, Tonnis grade II or higher radiographic osteoarthritis, congenital hip deformities including Legg-Calve-Perthes or Slipped Capital Femoral Epiphysis, rheumatologic conditions, or workers compensation claims.\n* Patients undergoing additional arthroscopic procedures such as trochanteric bursectomy or gluteus medius repair will also be excluded.","16 Years",{"count":73,"type":20},[23],"The purpose of this study is to see if bone marrow aspirate concentrate (BMAC) used with your hip arthroscopy surgery is a better treatment than just having surgery alone for treatment of labral tears in your hip.\n\nBMAC is an injection, where your doctor will insert a needle into your hip and harvest the bone marrow that is located inside of your bones. This will be performed under anesthesia during your hip arthroscopy surgery and will be injected during the procedure. BMAC is an FDA approved procedure and has had many research articles produced from it.\n\nResearchers will compare patients who received BMAC during their surgery to those who have not to determine if the injection with surgery is better than surgery alone.",[98,99],"Labral Tear","Femoroacetabular Impingement",[101,102,103],"hip arthroscopy","bone marrow aspirate concentrate","orthobiologics","2024-12-20",{"date":106,"type":36},"2024-12-27",{"date":108,"type":20},"2025-02",{"date":110,"type":20},"2028-02",{"name":42,"class":43},""]